Formulation of Sustained Release Zolpidem Tartrate Matrix Tablets Through Optimization and Their Evaluation

被引:0
作者
Khan, Masheer Ahmed [1 ]
Chaturvedi, S. C. [1 ]
机构
[1] Devi Ahilya Vishwavidyalaya, Sch Pharm, Indore 452001, Madhya Pradesh, India
关键词
Zolpidem tartrate; Matrix tablets; Sustained release; HPMC; Polymer; Factorial design; SLEEP MAINTENANCE; EXTENDED-RELEASE; INDUCTION;
D O I
暂无
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The object of the present study is to develop sustained release system of the hypnotic agent zolpidem useful for the treatment of insomnia. Matrix tablet is the least complicated device to sustain the release of drug candidates. Two polymers HPMCK4M and HPMCK15M were selected to sustain the release up to 12 h. Optimization techniques using factorial design for two factors at three levels (3(2)) was selected to optimize varied response variables viz., release rate exponent (n), t(50) %, k, amount of drug released in 12 h and mean dissolution time. Software Zorel was used to calculate the release kinetics. The design expert software was used to generate ANOVA for selected five responses. The optimum formulations were selected and the results obtained with the experimental values were compared with the predicted values. Furthermore, the in vitro and in vivo studies were performed with newly formulated sustained-release zolpidem tablets and were compared with conventional marketed tablet (zoldem). In vivo investigation in rabbits showed sustained-release pharmacokinetic profile of zolpidem from the matrix tablets formulated using combination of HPMCK4M and HPMCK15M. In conclusion, the results suggest that the developed sustained-release matrix tablets could provide quite regulated release of zolpidem tartrate up to nearly 12 h.
引用
收藏
页码:4749 / 4762
页数:14
相关论文
共 22 条
[1]  
[Anonymous], MODERN PHARM
[2]  
BARKIN RL, AM J THER, V14, P299
[3]  
Bolton S., 1990, Pharmaceutical statistics: practical and clinical applications, V2nd ed.
[4]  
Box GEP., 1960, The Design and Analysis of Industrial Experiments, V2nd
[5]   Effects of excipients on swelling and drug release from compressed matrices [J].
Efentakis, M ;
Vlachou, M ;
Choulis, NH .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1997, 23 (01) :107-112
[6]   Determination of zolpidem hemitartrate by quantitative HPTLC and LC [J].
El Zeany, BA ;
Moustafa, AA ;
Farid, NF .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2003, 33 (03) :393-401
[7]   Dynamics and kinetics of a modified-release formulation of zolpidem: Comparison with immediate-release standard zolpidem and placebo [J].
Greenblatt, David J. ;
Legangneux, Eric ;
Harmatz, Jerold S. ;
Weinling, Estelle ;
Freeman, Jon ;
Rice, Kathleen ;
Zammit, Gary K. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (12) :1469-1480
[8]  
Kuksal A, 2006, AAPS PHARMSCITECH, V7, DOI 10.1208/pt070101
[9]   Determination and in-process control of zolpidem synthesis by high-performance liquid chromatography [J].
Laviana, L ;
Mangas, C ;
Fernández-Marí, F ;
Bayod, M ;
Blanco, D .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2004, 36 (04) :925-928
[10]  
LEWIS G.A., 1999, PHARM EXPT DESIGN DR